0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IDH1

IDH1

IDH1 Molecule Information

Name:Isocitrate dehydrogenase [NADP] cytoplasmic
Target Synonym:Isocitrate Dehydrogenase [NADP] Cytoplasmic,IDH,EC 1.1.1.42,HEL-216,HEL-S-26,IDH1,Cytosolic NADP-Isocitrate Dehydrogenase,NADP(+)-Specific ICDH,IDP,Isocitrate Dehydrogenase (NADP(+)) 1, Cytosolic,IDCD,PICD,Isocitrate Dehydrogenase 1 (NADP+), Soluble,Isoci
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:9
Lastest Research Phase:Approved

IDH1 Molecule Synonym Name

IDH1,PICD,IDP

IDH1 Molecule Background

Isocitrate dehydrogenase 1 (IDH1) is also known as Cytosolic NADP-isocitrate dehydrogenase (NADP(+)-specific ICDH), Oxalosuccinate decarboxylase and PICD, which is one of the Isocitrate dehydrogenases that can catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutarate. These enzymes belong to two distinct subclasses, one of which utilizes NAD+ as the electron acceptor and the other NADP+. The cytoplasmic enzyme serves a significant role in cytoplasmic NADPH production.

IDH1 References

IDH1 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Ivosidenib AG-120; CS-3010 Approved Celgene Corp, Agios Pharmaceuticals Tibsovo United States Leukemia, Myeloid, Acute s:25:"Agios Pharmaceuticals Inc"; 2018-07-20 Leukemia; Chondrosarcoma; Biliary Tract Neoplasms; Leukemia, Myeloid; Myelodysplastic Syndromes; Cholangiocarcinoma; Hepatic Insufficiency; Bile Duct Neoplasms; Leukemia, Myeloid, Acute; Glioma Details

IDH1 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
IDH-305 IDH-305 Phase 2 Clinical Novartis Pharma Ag Neoplasms; Leukemia, Myeloid, Acute; Glioma Details
BAY-1436032 BAY-1436032 Phase 1 Clinical Bayer Ag Neoplasms; Leukemia, Myeloid, Acute Details
IDH1 peptide vaccine (German Cancer Research Center) Phase 1 Clinical Deutsches Krebsforschungszentrum, Dkfz Glioma Details
DS-1001 DS-1001b; DS-1001 Phase 2 Clinical Daiichi Sankyo Co Ltd Glioma Details
Olutasidenib FT-2102 Phase 2 Clinical Forma Therapeutics Chondrosarcoma; Irritable Bowel Syndrome; Clostridium Infections; Myelodysplastic Syndromes; Glioblastoma; Diarrhea; Leukemia, Myeloid, Acute; Glioma Details
Vorasidenib AG-881 Phase 3 Clinical Celgene Corp, Agios Pharmaceuticals Hematologic Neoplasms; Biliary Tract Neoplasms; Myelodysplastic Syndromes; Sarcoma; Leukemia, Myeloid, Acute; Glioma Details
HMPL-306 HMPL-306 Phase 1 Clinical Hutchison Medipharma Ltd Hematologic Neoplasms; Solid tumours; Leukemia, Myeloid, Acute Details
HH-2301 Phase 1 Clinical Chondrosarcoma; Biliary Tract Neoplasms; Solid tumours; Glioma Details
LY-3410738 LY-3410738 Phase 1 Clinical Eli Lilly And Company Chondrosarcoma; Myelodysplastic Syndromes; Myeloproliferative Disorders; Leukemia, Myelomonocytic, Chronic; Cholangiocarcinoma; Leukemia, Myeloid, Acute; Glioma Details
TQB-3455 TQB-3455 Phase 1 Clinical Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd, Lianyungang Runzhong Pharmaceutical Co Ltd, Beijing Sailintai Medicine Technology Co Ltd Solid tumours; Hematologic Neoplasms; Leukemia, Myeloid, Acute Details

This web search service is supported by Google Inc.

totop